Raji-Human CD19 Knockout-Stable Cell Line
| Catalog Number | CBCL-0605 |
| Price | Online Inquiry |
| Unit Quantity | 5 x 10^6 cells / 1.0 ml |
Introduction
The Raji-Human CD19 Knockout-Stable Cell Line is generated from Raji cells through targeted knockout of human CD19 (Gene ID: 930). The expression level of human CD19 is confirmed by flow cytometry. Mutated sequences of human CD19 produced by non-homologous end joining (NHEJ) are confirmed through genomic sequencing.
Application
Useful for cell-based CD19 target-specific analysis
Background
CD19 is a B cell-specific surface glycoprotein expressed throughout B cell development (pro-B to mature B cells). It forms a co-receptor complex with CD21 and CD81, lowering the threshold for B cell activation by antigens. CD21 is a key target for CAR-T cell therapy in B cell malignancies (e.g., leukemia, lymphoma).
Product Information
| Category | CAR-T Therapy Cell Lines |
| Cell Line Name | Raji-Human CD19 Knockout-Stable Cell Line |
| Protein Family | CD19 family |
| Gene | CD19 |
| NCBI Gene ID | 930 |
| Species | Human |
| Host Cell Line | Raji |
| Cell Type | Human B-cell lymphoma |
| Morphology | Lymphoblastoid |
| Growth Properties | Suspension |
| Storage Method | Frozen in liquid nitrogen. |
| Stability | Validated for at least 10 passages |
| Mycoplasma | Negative |
| Sterility Testing | Negative |
| Shipping | Shipping in dry ice |
| Caution | For Research Use Only |
For research use only. Not for any other purpose.